816 related articles for article (PubMed ID: 23299465)
1. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
Wong H; Chow TW
J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
[TBL] [Abstract][Full Text] [Related]
4. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
Li L; Gardner I; Dostalek M; Jamei M
AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
[TBL] [Abstract][Full Text] [Related]
5. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology and therapeutic applications of monoclonal antibodies.
Castelli MS; McGonigle P; Hornby PJ
Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
Glassman PM; Balthasar JP
Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
[TBL] [Abstract][Full Text] [Related]
9. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.
Edlund H; Melin J; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2015 Jan; 54(1):35-80. PubMed ID: 25516414
[TBL] [Abstract][Full Text] [Related]
11. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
12. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
13. Application of FcRn binding assays to guide mAb development.
Datta-Mannan A; Wroblewski VJ
Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
Mould DR; Green B
BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
[TBL] [Abstract][Full Text] [Related]
15. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
16. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
17. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
Front Immunol; 2014; 5():670. PubMed ID: 25601866
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.
Ferl GZ; Theil FP; Wong H
Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]